全國服務咨詢熱線：
18438616290
18438616290
產品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 95058-81-4 |
|---|---|---|---|
| 分子式 | C9H11F2N3O4 | 純度 | ＞98% |
| 分子量 | 263.2 | 貨號 | abs47026943 |
| 規格 | 10mg | 供貨周期 | 現貨 |
| 主要用途 | is a nucleoside metabolic inhibitor in | 應用領域 | 化工,生物產業,農林牧漁,制藥/生物制藥,綜合 |
| 產品描述 | |
| 描述 | Gemcitabine is a nucleoside metabolic inhibitor in PANC1（IC50=50 nM）, MIAPaCa2（IC50=40 nM）, BxPC3（IC50=18 nM） and Capan2 cells（IC50=12 nM）. |
| 純度 | ＞98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 吉西他濱；NSC 613327；LY188011 |
| 外觀 | 白色至淺黃色粉末 |
| 可溶性/溶解性 | DMSO : 15 mg/mL (56.99 mM) |
| 生物活性 | |
| 靶點 | DNA_RNA Synthesis |
| In vitro(體外研究) | MTS assay demonstrates that Gemcitabine at 15 nM, indole-3-carbinol (I3C) at 50 μM and the combination does not affect hTERT-HPNE cell viability. However, treatment with Gemcitabine at 15 nM, I3C at 50 μM and the combination results in 31%, 19% and 72% cell death of BxPC-3 cells, respectively. |
| In vivo(體內研究) | Treatment of the LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre mice with either Gemcitabine (50 mg/kg, i.p.) or the combination DMAPT/Gemcitabine significantly increased the median survival time by more than 30 days compared to the placebo group (254.5 or 255 days vs. 217.5 days, respectively). Gemcitabine can be administered via endotracheal spray in rats without marked toxicity with a maximum tolerated dose of 4 mg/kg once a week for 9 weeks. The toxicity of Gemcitabine is lower via lung than oral administration at dosages of 2, 4, and 6 mg/kg. |
| 參考文獻 | |
| 參考文獻 |
|
| 研究領域 | |
| 研究領域 | CancerCancer Metabolism CancerTumor biomarkers CancerTumor immunology Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產品咨詢
地址：上海市浦東新區新浩路58號申江科創園18棟
郵箱：lanwu@univ-bio.com
傳真：